CLYMHealthcare · BiotechnologyCLYM Stock Forecast: Climb Bio, Inc. Price Predictions for 2026-2027
The 13 Wall Street analysts covering Climb Bio, Inc. hold a median 12-month price target of $20 — +69.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 72 of 100 as at 1 Aug 2026 — in the upper half. Here, the model and the Street point the same way.
CLYM stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Climb Bio, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (99): The shares have been drifting up relative to others.
Volatility (29): The share price moves around a lot.
The rank is the raw material. Whether the rules would actually own Climb Bio, Inc. — and when they’d sell — is the membership.
CLYM stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on CLYM, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +69.3% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 27 July 2026 | Wedbush | Maintains | Outperform | $17 → $20 |
| 24 June 2026 | HC Wainwright & Co. | Reiterates | Buy | $20 |
| 24 June 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 12 June 2026 | Wedbush | Reiterates | Outperform | — |
| 11 June 2026 | BTIG | Maintains | Buy | — |
| 8 June 2026 | BTIG | Reiterates | Buy | — |
| 8 June 2026 | Guggenheim | Initiates | Buy | — |
| 12 May 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 8 May 2026 | Wedbush | Maintains | Outperform | — |
| 6 May 2026 | BTIG | Maintains | Buy | — |
| 5 May 2026 | Chardan Capital | Initiates | Buy | — |
| 21 Apr 2026 | Oppenheimer | Maintains | Outperform | — |
| 15 Apr 2026 | Mizuho | Initiates | Outperform | — |
| 8 Apr 2026 | BTIG | Reiterates | Buy | — |
| 24 Mar 2026 | B. Riley Securities | Initiates | Buy | — |
| 18 Mar 2026 | Truist Securities | Initiates | Buy | — |
| 11 Mar 2026 | Raymond James | Initiates | Strong Buy | — |
| 10 Mar 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 6 Mar 2026 | Baird | Maintains | Outperform | — |
| 6 Mar 2026 | Wedbush | Maintains | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
CLYM analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Climb Bio, Inc. (CLYM) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- −13.0×
- Price / sales
- —
- Price / book
- 3.7×
- EV / EBITDA
- −8.5×
Cheaper than 94% of US stocks
Cheaper than 28% of US stocks
Cheaper than 83% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- 0.0%
- Net margin
- 0.0%
Higher than 35% of US stocks
Higher than 30% of US stocks
- Return on equity
- −30.9%
- Return on assets
- −21.3%
- Dividend yield
- —
Higher than 26% of US stocks
Higher than 19% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
CLYM vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CLYM appears on the weeks it earns a place.
Frequently asked questions about CLYM stock
What is the CLYM stock price forecast for 2026-2027?
The 13 Wall Street analysts covering Climb Bio, Inc. have a median 12-month price target of $20, with estimates ranging from $15 to $35. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is CLYM stock a buy right now?
Of the 13 analysts covering Climb Bio, Inc., 13 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Climb Bio, Inc. 72 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank CLYM?
As at 1 Aug 2026, Climb Bio, Inc. ranks 72 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (99 of 100).
Will CLYM stock go up?
No one can know that. What the data says: the median 12-month target from 13 analysts implies +69.3% from the last close, and Ticker Nerd's factor model ranks Climb Bio, Inc. 72 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the CLYM stock forecast for 2030?
No analyst covering Climb Bio, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CLYM are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $15 to $35 over the next 12 months.
How has CLYM stock performed over the past year?
Climb Bio, Inc. returned +714.5% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Climb Bio, Inc. do?
Climb Biotherapeutics, Inc. is a company in the biotechnology industry, focusing on the development and commercialization of novel therapeutic solutions.
About Climb Bio, Inc.
Climb Biotherapeutics, Inc. is a company in the biotechnology industry, focusing on the development and commercialization of novel therapeutic solutions. Primarily, it plays a role in advancing treatments for conditions that lack efficient medical solutions, positioning itself at the forefront of innovation in health care. The company's research and product pipeline frequently encompasses diverse therapeutic areas, leveraging cutting-edge technology and research methodologies to target complex biological processes. Climb Biotherapeutics impacts sectors such as pharmaceuticals, medical research, and health services, contributing vital new approaches that could transform patient care standards. Within the financial markets, it holds significance as a biotech entity potentially providing new breakthroughs that may influence industry standards and economic evaluations. By aiming to tackle unmet medical needs, Climb Biotherapeutics is a key player in potentially altering disease management protocols and enhancing health outcomes, thus maintaining a critical role in both the scientific community and the financial ecosystem where health innovation is a focal point of interest.
CEO Dr. Aoife M. Brennan BAO, BCh, M.D., MB, MMSc · 28 employees · United States · https://climbbio.com